| Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting J Betge, MJ Pollheimer, RA Lindtner, P Kornprat, A Schlemmer, P Rehak, ... Cancer 118 (3), 628-638, 2012 | 341 | 2012 |
| CRISPR/Cas9 for cancer research and therapy T Zhan, N Rindtorff, J Betge, MP Ebert, M Boutros Seminars in cancer biology 55, 106-119, 2019 | 319 | 2019 |
| MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer T Zhan, G Ambrosi, AM Wandmacher, B Rauscher, J Betge, N Rindtorff, ... Nature communications 10 (1), 2197, 2019 | 141 | 2019 |
| Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer J Betge, P Kornprat, MJ Pollheimer, RA Lindtner, A Schlemmer, P Rehak, ... Annals of surgical oncology 19, 3706-3712, 2012 | 131 | 2012 |
| MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance J Betge, NI Schneider, L Harbaum, MJ Pollheimer, RA Lindtner, ... Virchows Archiv 469, 255-265, 2016 | 125 | 2016 |
| Lymph node retrieval in colorectal cancer: determining factors and prognostic significance J Betge, L Harbaum, MJ Pollheimer, RA Lindtner, P Kornprat, MP Ebert, ... International journal of colorectal disease 32, 991-998, 2017 | 81 | 2017 |
| Prognostic cancer gene expression signatures: current status and challenges Y Qian, J Daza, T Itzel, J Betge, T Zhan, F Marmé, A Teufel Cells 10 (3), 648, 2021 | 59 | 2021 |
| Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy D Smeets, IS Miller, DP O’Connor, S Das, B Moran, B Boeckx, T Gaiser, ... Nature communications 9 (1), 4112, 2018 | 59 | 2018 |
| Apelin: a putative novel predictive biomarker for bevacizumab response in colorectal cancer L Zuurbier, A Rahman, M Cordes, J Scheick, TJ Wong, F Rustenburg, ... Oncotarget 8 (26), 42949, 2017 | 54 | 2017 |
| Vascular invasion, perineural invasion, and tumour budding: predictors of outcome in colorectal cancer J Betge, C Langner Acta gastro-enterologica Belgica 74 (4), 516-29, 2011 | 49 | 2011 |
| Tumor size, tumor location, and antitumor inflammatory response are associated with lymph node size in colorectal cancer patients O Rössler, J Betge, L Harbaum, K Mrak, J Tschmelitsch, C Langner Modern Pathology 30 (6), 897-904, 2017 | 43 | 2017 |
| Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth … E Burgermeister, F Battaglin, F Eladly, W Wu, F Herweck, N Schulte, ... EBioMedicine 45, 139-154, 2019 | 42 | 2019 |
| Amplicon sequencing of colorectal cancer: variant calling in frozen and formalin-fixed samples J Betge, G Kerr, T Miersch, S Leible, G Erdmann, CL Galata, T Zhan, ... PLoS One 10 (5), e0127146, 2015 | 37 | 2015 |
| Loss of chromosome 18q11. 2-q12. 1 is predictive for survival in patients with metastatic colorectal cancer treated with bevacizumab E Van Dijk, HD Biesma, M Cordes, D Smeets, M Neerincx, S Das, PP Eijk, ... Journal of Clinical Oncology 36 (20), 2052-2060, 2018 | 34 | 2018 |
| Risk factors for local recurrence of large, flat colorectal polyps after endoscopic mucosal resection T Zhan, T Hielscher, F Hahn, C Hauf, J Betge, MP Ebert, S Belle Digestion 93 (4), 311-317, 2016 | 34 | 2016 |
| Patient-derived organoids of cholangiocarcinoma CF Maier, L Zhu, LK Nanduri, D Kühn, S Kochall, ML Thepkaysone, ... International journal of molecular sciences 22 (16), 8675, 2021 | 28 | 2021 |
| A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine+/− nab-paclitaxel in elderly pancreatic cancer patients (GrantPax) J Betge, J Chi-Kern, N Schulte, S Belle, T Gutting, E Burgermeister, ... BMC cancer 18, 1-7, 2018 | 27 | 2018 |
| The drug-induced phenotypic landscape of colorectal cancer organoids J Betge, N Rindtorff, J Sauer, B Rauscher, C Dingert, H Gaitantzi, ... Nature Communications 13 (1), 3135, 2022 | 26 | 2022 |
| Precision medicine for metastatic colorectal cancer in clinical practice JE Riedesser, MP Ebert, J Betge Therapeutic Advances in Medical Oncology 14, 17588359211072703, 2022 | 26 | 2022 |
| A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA) NM Meindl-Beinker, J Betge, T Gutting, E Burgermeister, S Belle, T Zhan, ... BMC cancer 19, 1-8, 2019 | 20 | 2019 |
